3. Adverse effects for other comparisons.
|
Study |
Comparison | GI | CNS | Injection site | Other | |||||
| Drug 1 | Drug 2 | Drug 1 | Drug 2 | Drug 1 | Drug 2 | Drug 1 | Drug 2 | Drug 1 | Drug 2 | |
| Iguchi 2002 | Butylscopolamine | Lidocaine | No adverse effects were observed | |||||||
| Romics 2003 | Drotaverine | Placebo | 20 patients in drotaverine, 4 in placebo had mild adverse effects | |||||||
| Bahn Zobbe 1986 | Glucagon | Placebo | 11/18 | 1/19 | 0 | 0 | 0 | 0 | 3 | 0 |
| Caravati 1989 | Nifedipine | Placebo | 1/13 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Miano 1986 | Tyropramide | Butylscopolamine | 3/103 | 4/96 | 7 | 6 | 0 | 0 | 2 | 8 |
CNS ‐ central nervous system; GI ‐ gastrointestinal